WASHINGTON (AP) -- What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?...
Study outcome won't sway company on eye drugCourtesy Headlines from the Associated Press Wed, 08/27/2008 - 12:18
WASHINGTON (AP) -- What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?... More related itemsFDA clears first implantable telescope for vision
New 'research' fee to hit your health insurance plan
New child-adapted Chagas disease treatment approved...
The Unwritten Rules of Friendship: Simple Strategies...
|
Popular by tags WeekMonth |
Post new comment